From The Stage

Proof of Concept to Solution: A Unique Approach to Anti-PEG Antibodies Assessment

Jeff Sailstad
Posted by Jeff Sailstad / / BioAgilytix Insight, Immunogenicity

BioAgilytix recently had the opportunity to work on a particularly difficult clinical phase anti-drug antibody (ADA) assessment for an innovative PEGylated drug therapy designed to treat a serious chronic condition. Jeff Sailstad, our USA Chief Scientific Officer, explains how our team approached the unique challenges of this assessment.